PlainPill

Ghrh

Based on 3 first-hand reports and 6 meta-analyses & systematic reviews in the medical literature. Ranked #2825 of 3,539 overall.

6
User score
Not enough data
0% positive0% mixed0% negative100% unclear

Of reports that state an outcome, 0% are positive.

Clinical research
AStrong research base
6
meta-analyses
241
RCTs
3,871
papers
High-risk compound. Peptides are not approved as supplements, carry serious and sometimes irreversible risks, are banned in competitive sport and may be restricted where you live. Nothing here is a recommendation to use it.

What Ghrh does, according to users

Of the people who reported each effect, the share who said it got better.

No specific effects reported yet.
betterno changeworse

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found.

Andrology · 2017 · Meta-analysis / systematic review
The impact of drugs on male fertility: a review

Conclusion: When a reprotoxic treatment cannot be stopped and/or when the impact on semen parameters/sperm DNA is potentially irreversible (Sulfasalazine Azathioprine, Mycophenolate mofetil and Methotrexate), the cryopreservation of spermatozoa before treatment must be proposed. Deleterious impacts on fertility of drugs with very good or good level of evidence (Testosterone, Sulfasalazine, Anabolic steroids, Cyproterone acetate, Opioids, Tramadol, GhRH analogues and Sartan) are developed.

PubMed 28622464 ↗
HIV Med · 2011 · Meta-analysis / systematic review
Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials

Conclusion: Our review indicates that, based on the findings of the 10 included studies, GH axis treatments are effective in reducing VAT and increasing LBM in patients with HIV-associated lipodystrophy. However, clinicians must decide whether the attributed benefits are clinically significant, considering the costs and potential risks of GH axis treatments. A limitation of this study is the small number of studies available of each GH axis drug class.

PubMed 21265979 ↗

Dosage people report

As stated by users — not a recommendation. Follow the label or your doctor.

No doses stated in the reports so far.

Reported side effects

How often each side effect came up across all reports.

No side effects reported so far.

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

More peptides

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 3, 2026. How we rate